MEDIBO

Medibo is a South Korean biotechnology company specializing in the development and manufacture of synthetic bone graft materials and tissue engineering solutions. Founded in 2014, the company focuses on biomimetic materials that facilitate bone regeneration in orthopedic, dental, and spinal surgeries. Its flagship product line, Bongros, utilizes hydroxyapatite (HA) and tricalcium phosphate (TCP) technologies to provide scaffolds for new bone growth. Medibo's products are designed to be biocompatible and osteoconductive, addressing clinical needs in bone defect repair and implant stability. The company operates primarily in the medical device and regenerative medicine sectors, with a strong presence in the Asian market.